RADIOTHERAPY
JUST Leveled Up



Watch video

 

Turning cancer on
itself > Finally

SCINTIX® biology-guided radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.

SELF-DRIVING RADIOTHERAPY

Cancer is talking.
We’re listening.

When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our X1 platform uses to manage motion and treat solid tumors of any stage disease.

Learn About Emissions

Targeting Cancer

GOOD NEWS FOR ORGANS.
BAD NEWS FOR TUMORS.

Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.

Learn About Targeting

ANY STAGE TUMOR

A world where stage
is just a number.

Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.

Discover the Potential

Combination Treatment

Come at cancer
from every angle.

Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.

Learn About Treatment

Learn more about our breakthrough technology

SCINTIX Biology-guided Radiotherapy

By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.

Clinicians

Discover SCINTIX therapy.

Cancer Centers

See how SCINTIX therapy can play a role
in your cancer program.

Make every day count

See Available Positions

Latest

Press Releases

RefleXion to Share Groundbreaking Research in 37 Scientific Presentations at the AAPM 2024 Annual Meeting

Company to introduce significant product upgrades that enable treating multiple tumors in a single treatment plan to improve patient experience. HAYWARD, Calif., July 20, 2023 – RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from multiple clinical programs will present pioneering scientific evidence in 37 oral and poster presentations confirming the efficacy […]

View All Press chevron right

Blog

SCINTIX Therapy Expands in the Northeast

The ribbon cutting at Smilow Cancer Hospital on January 4, 2024, marked a significant milestone in that it has become the first hospital in Connecticut to offer RefleXion Medical’s breakthrough SCINTIX® biology-guided radiotherapy (BgRT). Approximately 430,000 people in the United States are diagnosed annually with tumors originating within or spreading to the lungs or bones. […]

View All Blog Posts chevron right

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up